---
title: "GRAIL to Present at the 2026 Jefferies Global Healthcare Conference | GRAL Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287265991.md"
description: "GRAIL, Inc. (Nasdaq: GRAL) will present at the 2026 Jefferies Global Healthcare Conference on June 3 at 7:35 a.m. ET. The event will be accessible via live and replay webcasts on GRAIL's investor relations website. GRAIL focuses on early cancer detection using advanced technologies."
datetime: "2026-05-21T12:01:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287265991.md)
  - [en](https://longbridge.com/en/news/287265991.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287265991.md)
---

# GRAIL to Present at the 2026 Jefferies Global Healthcare Conference | GRAL Stock News

, /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3 at 7:35 a.m. ET.

Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.

**About GRAIL  
**GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

SOURCE GRAIL, Inc.

### Related Stocks

- [GRAL.US](https://longbridge.com/en/quote/GRAL.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)

## Related News & Research

- [Geode Capital Management LLC Has $68.61 Million Position in GRAIL, Inc. $GRAL](https://longbridge.com/en/news/289160247.md)
- [Here's Why Grail Stock Soared Higher in May (And Where the Company is Heading Now)](https://longbridge.com/en/news/288857741.md)
- [GRAIL Presents Positive PATHFINDER 2 Results Of Galleri MCED Test At ASCO 2026](https://longbridge.com/en/news/288228856.md)
- [GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint](https://longbridge.com/en/news/288192997.md)
- [Here's What Analysts Are Forecasting For GRAIL, Inc. (NASDAQ:GRAL) After Its First-Quarter Results](https://longbridge.com/en/news/285738527.md)